retatrutide lilly The FDA has issued warning letters to multiple companies marketing compounded Retatrutide, an investigational drug from Eli still in Phase II trials. While early studies have shown promising weight-loss results, Eli Lilly's Next-Gen Obesity Drug

Review the sources used below for this article: This article references information from a study published in the BMJ: Risk of hair loss associated with glucagon-like peptide-1 receptor agonists in adults with type 2 diabetes: target trial emulation

Eligibility details for Medicare GLP-1 weight loss drugs under the new Bridge program: People with BMIs of 35 or greater

They are also contraindicated in those with personal or family history of medullary thyroid carcinoma and those with multiple endocrine neoplasia type 2

In the rodent studies, this overgrowth (hyperplasia) eventually led to medullary thyroid tumours

You can find all of our Brave New World content in the U.S